Lilly(US:LLY)2026-02-04 16:00Financial Data and Key Metrics Changes - In 2025, full-year revenue reached $65.2 billion, a 45% increase compared to 2024, with earnings per share growing by 86% to $24.21 [4][8] - Q4 revenue grew 43% compared to Q4 2024, with gross margin at 83.2%, consistent with Q4 2024 [8][9] - Non-GAAP performance margin was 47.2%, an increase of 4.2 percentage points compared to Q4 2024 [8] Business Line Data and Key Metrics Changes - Key products contributed over $13 billion to revenue in Q4, growing by 91% compared to Q4 2024 [10] - Kisunla became the U.S. market leader in amyloid-targeting therapy with over 50% market share, generating $109 million in revenue [10] - Zepbound revenue more than doubled compared to Q4 2024, maintaining nearly 70% share of new prescriptions in the branded obesity market [12] Market Data and Key Metrics Changes - U.S. revenue increased 43% in Q4, driven by volume growth of Mounjaro and Zepbound, despite a 7% decline in price [9] - International revenue growth was strong, with double-digit volume growth in Europe, Japan, and China, and volume doubling in the rest of the world due to Mounjaro's launch [9][10] Company Strategy and Development Direction - The company executed 39 business development transactions and expanded its manufacturing footprint, committing over $55 billion since 2020 [5][6] - Plans to launch Orforglipron for chronic weight management in the U.S. in Q2 2026, with expectations for significant market expansion [15][16] - The company aims to leverage AI for drug discovery and has partnered with NVIDIA to enhance its capabilities [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory in the U.S. incretin analogs market and anticipated continued robust growth in 2026 [15] - The company expects revenue between $80 billion and $83 billion in 2026, a 25% increase from 2025, despite anticipated pricing pressures [13][16] - Management highlighted the importance of expanding access to obesity medications through Medicare and Medicaid [6][16] Other Important Information - The company distributed $1.3 billion in dividends and $1.5 billion in share repurchases in 2025 [6] - The leadership team was strengthened with the addition of two new executives [7] Q&A Session Summary Question: Metrics for Orforglipron's Launch - Management indicated they would track market expansion and patient satisfaction as key metrics for Orforglipron's success [39][40] Question: Accelerated Approval Pathways for Orforglipron - Management expects most international launches for Orforglipron to occur in late 2026 and 2027, with some exceptions [44] Question: International Mounjaro Growth - Management noted that Q4 served as a strong base for 2026 growth, with a focus on market expansion and reimbursement strategies [50] Question: Investment in Immunology - Management emphasized ongoing investments in immunology and the potential for combination therapies to enhance treatment outcomes [56] Question: Medicare Volume Ramp Impact - Management expects a significant number of patients to transition to Medicare, which will positively impact revenue growth [62][63] Question: Combination Therapies with Zepbound - Management is exploring various combination therapies to address immune diseases and obesity, with ongoing trials expected to yield promising results [71][72] Question: Pricing Dynamics in the Incretin Portfolio - Management discussed ongoing discussions with PBMs to expand access and the importance of affordability in driving utilization [76] Question: Importance of Obesity-Related Indications - Management sees growing evidence supporting the coverage of obesity medications for various comorbidities, which could enhance long-term market opportunities [82]